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Objectives. We hypothesized that if the Electrophysiology Study 
Versus Electrocardiographic Monitoring (ESVEM) trial pro- 
grammed stimulation protocol misclassified some drug trials as 
effective, then the misclassifieation rate would be proportionally 
greater for drugs other than sotaloi. 
Background. In the ESVEM trial, patients treated with sotalol 
had fewer arrhythmie recurrences than those treated with other 
antiarrhythmic drugs despite similar efficacy predictions during 
electrophysiologic testing. 
Methods. We retrospectively compared the standard pro- 
grammed stimulation protocol used at Case Western Reserve 
University, which used three extrastimuli during all follow-up 
studies, with the ESVEM protocol in 176 antiarrhythmic drug 
trials: sotalol (n = 54), procainamide (n = 73) and quinidine/ 
mexiletine (n = 49). 
Results. Predictions of efficacy were higher in the sotalol trials 
(14 of 54 standard, 20 of 54 ESVEM) than in proeainamide trials 
(7 of 73 standard, 14 of 73 ESVEM) or quinidine/mexiletine trials 
(1 of 49 standard, 7 of 49 ESVEM). Thus, the two protocols 
classified 19 of 176 trials differently: not effective by the standard 
protocol but effective by the ESVEM trial. Discordant predictions 
of drug efficacy constituted a smaller proportion of ESVEM 
protocol efficacy predictions for sotalol (6 [30%] of 20) than for 
the other drugs (13 [62%] of 21, p < 0.05). 
Conclusions. In the present study, the ESVEM programmed 
stimulation protocol predicted efficacy more often than the stan- 
dard protocol. Discordant predictions represented a smaller 
portion of efficacy predictions for sotaiol than for the other drugs. 
Thus, in the ESVEM trial, the superior long-term follow-up 
observed in patients assigned to sotalol may have been an artifact 
of the stimulation protocol utilized by the ESVEM investigators. 
(J Am Coil Cardio11995;25:1601- 4) 
In the Electrophysiology Study Versus Electrocardiographic 
Monitoring (ESVEM) trial (1), serial electrophysiologic test- 
ing was compared with serial 24-h ambulatory (Holter) moni- 
toring for guiding antiarrhythmic drug treatment of ventricular 
tachycardia. SotaM suppressed induction of ventricular tachy- 
cardia more often than the other drugs utilized in the study 
(35% vs. 16%). The efficacy of sotalol in suppressing the 
induction of ventricular tachycardia n other studies has been 
consistent at -35% (2,3). However, these studies utilized 
different stimulation protocols and included patients with 
diverse clinical characteristics. 
A somewhat surprising finding in the ESVEM trial was that 
among patients whose therapy was guided by electrophysi- 
ologic study, sotalol was associated with fewer arrhythmia 
recurrences than other antiarrhythmic drugs (30% vs. 60%, 
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respectively, at 2 years) despite equivalent electrophysiologi- 
cally guided efficacy predictions. The reason for this difference 
was not clear. According to the ESVEM investigators, this 
finding suggested that sotalol had unique effects that were not 
identified by electrophysiologic studies. 
The ESVEM programmed stimulation protocol utilized 
only two rather than three ventricular extrastimuli during 
follow-up studies when either one or two ventricular extra- 
stimuli induced ventricular tachycardia during the baseline 
study. The ESVEM programmed stimulation protocol utilized 
three ventricular extrastimuli during follow-up studies only 
when three extrastimuli induced ventricular tachycardia at the 
baseline study. Previous studies (4,5) have shown that the 
number of extrastimuli necessary to induce ventricular tachy- 
cardia may vary. We hypothesized that the ESVEM pro- 
grammed stimulation protocol classified drugs as effective 
during some trials that utilized only up to two extrastimuli 
when ventricular tachycardia would have been induced with 
three extrastimuli. Furthermore, we hypothesized that the 
nature of the ESVEM programmed stimulation protocol was 
responsible for the lower arrhythmia recurrence rate in pa- 
tients taking sotalol compared with those taking other anti- 
arrhythmic drugs. To test these hypotheses, we compared the 
ESVEM criteria for predicting antiarrhythmic drug efficacy for 
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ventricular tachycardia to criteria reported by other investiga- 
tors and used at our institution (standard protocol) (6,7). The 
standard protocol uses up to three extrastimuli at two right 
ventricular sites in all drug trials regardless of the results of the 
baseline study. 
Methods 
We analyzed the results of electrophysiologic studies in 125 
patients who presented to University Hospitals of Cleveland/ 
Case Western Reserve University with sustained ventricular 
tachycardia, after an aborted cardiac arrest or with syncope 
between 1989 and 1992. Each of the patients met the eligibility 
enrollment criteria for the ESVEM trial (8). Each patient 
underwent programmed ventricular stimulation in the absence 
of antiarrhythmic drugs (baseline study) using a protocol that 
included up to three premature xtrastimuli from two right 
ventricular sites after an 8-beat paced drive train at two cycle 
lengths. Double extrastimuli were completed at both sites 
before three extrastimuli were used. Sustained monomorphic 
ventricular tachycardia was induced and reinduced uring the 
baseline study in each patient. 
Each patient underwent one or two serial follow-up elec- 
trophysiologic studies in an attempt to find a drug that 
suppressed induction of ventricular tachycardia. Each 
follow-up study included up to three extrastimuli at two 
ventricular sites and two paced drive train cycle lengths 
regardless of the number of extrastimuli required to induce 
ventricular tachycardia during the baseline lectrophysiologic 
study. Double extrastimuli were completed at both sites before 
three extrastimuli were used. Antiarrhythmic drug efficacy 
using this protocol (standard protocol) was defined as inability 
to induce sustained ventricular tachycardia. The drugs tested 
included intravenous procainamide (15 mg/kg body weight), 
sotalol (160 to 480 mg/day) or the combination of quinidine 
gluconate (972 to 1,944 rag/day) and mexiletine (450 rag/day). 
We retrospectively applied the ESVEM criteria for predic- 
tion of drug efficacy based on electrophysiologic testing to each 
follow-up study. We compared the drug efficacy predictions of 
the standard protocol with those of the ESVEM protocol. 
Furthermore, we determined whether differences in the effi- 
cacy predictions of the two protocols depended on the drug 
tested. 
Statistics. Comparisons of drug trial results using the 
standard and ESVEM protocols were made using a chi-square 
analysis. 
Results 
The 125 patients underwent 176 follow-up electrophysi- 
ologic studies that were performed to determine the efficacy of 
antiarrhythmic drugs. Fifty-four drug trials were conducted 
with sotalol; 73 were conducted with procainamide, and 49 
were conducted with the combination of quinidine gluconate 
and mexiletine. 
During the baseline electrophysiologic study, ventricular 
tachycardia was induced with one extrastimulus in 15 patients, 
with two extrastimuli in 59 patients and with three extrastimuli 
in 51 patients. In six instances during reinduction at baseline, 
more extrastimuli were necessary to induce ventricular tachy- 
cardia. These baseline studies were classified according to the 
highest number of extrastimuli used to induce the ventricular 
tachycardia. 
Fifty-four patients were tested uring sotalol therapy using 
the standard protocol. Sotalol prevented induction of ventric- 
ular tachycardia in 14 (26%) of 54 patients. In six patients, 
ventricular tachycardia was induced with three extrastimuli 
during sotalol therapy, whereas it had been induced with one 
or two extrastimuli during the baseline study. Thus, the 
ESVEM protocol predicted sotalol efficacy in 20 patients 
(37%), whereas the standard protocol predicted the drug to be 
effective in only 14 (26%). 
Seventy-three patients were tested during procainamide 
therapy using the standard protocol. Procainamide prevented 
induction of ventricular tachycardia n 7 (10%) of 73 patients. 
In seven patients, ventricular tachycardia was induced with 
three extrastimuli during procainamide therapy, whereas it had 
been induced with one or two extrastimuli during the baseline 
study. Thus, the ESVEM protocol predicted procainamide 
efficacy in 14 patients (19%), whereas the standard protocol 
predicted the drug to be effective in 7 (10%). 
Forty-nine patients were tested uring quinidine gluconate 
and mexiletine administration using the standard protocol. 
Quinidine gluconate and mexiletine prevented induction of 
ventricu!ar tachycardia in only 1 (2%) of 49 patients. In six 
patients, ventricular tachycardia was induced with three extra- 
stimuli during quinidine gluconate and mexiletine therapy, 
whereas it had been induced with one or two extrastimuli 
during the baseline study. Thus, the ESVEM protocol pre- 
dicted quinidine gluconate and mexiletine fficacy in seven 
patients (14%), whereas the standard protocol predicted the 
drug combination to be effective in only one (2%). 
Overall, the ESVEM protocol classified 41 (23%) of 176 
drug trials as predicting efficacy, and the standard protocol 
classified 22 (12.5%) of 176 drug trials as predicting efficacy 
(p < 0.05). Thus, 19 of 143 drug trial results were discordant. 
All standard protocol drug trials predictive of failure were 
concordant with the ESVEM protocol predictions of failure. 
The overall discordance rate among trials was relatively con- 
stant among the different drugs: 6 (11%) of 54 for sotalol, 7 
(10%) of 73 for procainamide and 6 (12%) of 49 for quinidine/ 
mexiletine (p = NS) (Table 1). However, the discordance rate 
in trials with efficacy predictions was different among the three 
antiarrhythmic drug therapies tested. The discordant rate for 
sotalol efficacy prediction (30% [6 of 20]) was lower than that 
for the other drugs (procainamide or the combination of 
quinidine gluconate and mexiletine) tested (62% [13 of 21]) 
(p < 0.05) (Table 2). 
Thirteen of the 14 patients in whom ventricular tachycardia 
induction was suppressed by sotalol using the standard proto- 
col received the drug long term. In one patient he drug was 
discontinued before hospital discharge because of side effects. 
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Table 1. Results of 176 Electrophysiologic Trials in 125 Patients 
Undergoing Drug Testing to Suppress Ventricular 
Tachycardia Induction* 
Drug Trial 
No. (%) of No. (%) of 
Trials With Trials With 
ESVEM Standard 
Efficacy Efficacy 
Prediction Prediction 
No. (%) of 
Trials 
Discordant 
Between 
ESVEM 
and 
Standard 
Protocol 
Sotalol (n - 54) 20 (37%) 14 (26%) 6 (11%) 
Procainamide (n = 73) 14 (19%) 7 (10%) 7 (10%) 
Quinidine/mexiletine 7 (14%) 1 (2%) 6 (12%) 
(n = 49) 
*The discordance rate did not vary significantly among the drugs tested. 
The 13 other patients were followed up for a mean (_+SD) of 
29 _+ 10 months. Two deaths occurred from congestive heart 
failure at 6 and 24 months. Two arrhythmia recurrences 
occurred at 22 and 36 months. One recurrence, syncope, 
occurred in a patient who had discontinued sotalol therapy 
2 weeks before the episode. Since that event, this patient has 
been asymptomatic for an additional 14 months while taking 
sotalol. The other patient with an arrhythmia recurrence had 
documented sustained ventricular tachycardia. This patient 
had a cardioverter-defibrillator implanted and continued to 
receive sotalol. Since implantation, this patient has been 
without device discharge over a 9-month period. The remain- 
ing nine patients were free of symptoms. 
Discussion 
This study may, in part, explain the ESVEM finding that 
long-term outcome was better in patients assigned to sotalol 
therapy rather than to other antiarrhythmic drugs despite 
equivalent efficacy predictions. In the present study, the 
ESVEM programmed stimulation protocol predicted rug 
efficacy more often than did the standard protocol (41 [23%] of 
Table 2. Potential Misclassifications* 
Drug Trial 
No. (%) of Trials 
Discordant No. (%) of No. (%) of 
Between Trials With Discordant 
ESVEM and ESVEM Trials/ESVEM- 
Standard Efficacy Predicted 
Protocol Prediction Efficacy Trials 
Sotalol (n = 54) 6 (11%) 20 (37%) 6 of 20 (30%) 
Proeainamide 7 (10%) 14 (19%) 7 of 14 (50%) 
(n - 73) 
Quinidine/mexiletine 6 (12%) 7 (14%) 6 of 7 (86%) 
(n = 49) 
*If the discordant trials were misclassifications, then the misclassifications 
would be proportionately lower among patients assigned the higher predicted 
efficacy drug, sotalol, and proportionately higher among patients a signed the 
lower predicted fficacy drugs, procainamide or quinidine/mexiletine (30% [6 of 
20] vs. 62% [13 of 21], p -< 0.05). 
176 vs. 22 [12.5%] of 176, respectively). The ESVEM pro- 
grammed stimulation protocol predicted efficacy for 19 drug 
trials that were classified as ineffective by the standard proto- 
col. Overall discordant efficacy predictions between the stan- 
dard and ESVEM protocol were equally likely to occur 
regardless of the antiarrhythmic drug tested (6 of 49 for 
quinidine/mexiletine, 7 of 73 for procainamide or 6 of 54 for 
sotalol). However, despite an overall discordance rate that was 
similar for all drugs, the discordance rate among trials only 
predictive of efficacy varied among the drugs. When a drug was 
predicted more likely to be effective, the discordant trials 
became a smaller portion of the ESVEM trials predicting 
efficacy (6 of 20 for sotalol vs. 7 of 14 for procainamide and 6 
of 7 for quinidine/mexiletine). 
If the discordant efficacy predictions were misclassifications 
of drug efficacy by the ESVEM protocol, then patients as- 
signed to a drug with a lower overall efficacy prediction rate 
might be more likely to experience an arrhythmia recurrence. 
Thus, in the ESVEM trial, the programmed stimulation pro- 
tocol may have correctly predicted efficacy in a higher propor- 
tion of patients who received sotalol than those who received 
other antiarrhythmic drugs. Therefore, long-term outcome in 
patients who received sotalol may have been better because the 
protocol predicted efficacy better in those patients rather than 
because of an inherent drug effect not predicted by electro- 
physiologic study. 
Previous studies. The use of up to three ventricular extra- 
stimuli during every follow-up electrophysiologic study was not 
standard clinical practice when the ESVEM trial was designed. 
At that time, many investigators advocated using only two 
ventricular extrastimuli during follow-up electrophysiologic 
studies if one or two extrastimuli had induced ventricular 
tachycardia during the baseline study. Swerdlow et al. (9) 
showed no difference in arrhythmia-free survival between 
patients who underwent a protocol similar to ESVEM and 
those who underwent a protocol similar to the standard 
protocol. However, the short follow-up period and differences 
in the size of the two patient groups limit the clinical usefulness 
of the study. 
The results of the present study may be consistent with 
previous studies (4,5,7,10) that showed that the number of 
extrastimuli required to reinduee ventricular tachycardia c n 
vary both from day to day and within a single eleetrophysi- 
ologic study. Thus, ventricular tachycardia nduced with two 
extrastimuli might be induced with three extrastimuli at an- 
other time. Therefore, we and other investigators (6,7) advo- 
cate using up to three extrastimuli during all follow-up elec- 
trophysiologic studies regardless of the number of extrastimuli 
required to induce ventricular tachycardia during the baseline 
study. 
Long-term follow-up. The long-term follow-up of the 14 
patients in whom ventricular tachycardia was noninducible 
during sotalol therapy was similar to the experience of other 
investigators (2). In our series, sotalol was discontinued be- 
cause of side effects in one patient; two patients died of 
refractory congestive heart failure; and two patients had 
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nonfatal arrhythmia recurrences. Importantly, a sudden death 
did not occur. Direct comparison of these patients with those 
assigned to receive sotalol in the ESVEM trial is difficult. The 
ESVEM trial was a rigorous prospective study. Our long-term 
data are complete but retrospective. 
Study limitations. In the present study, because we could 
not determine long-term outcome in discordantly classified 
patients, we cannot state with any certainty that the ESVEM 
protocol overestimated drug efficacy. We can only speculate 
that many patients with arrhythmia recurrences in the ESVEM 
trial might have had ventricular tachycardia induced at the 
follow-up electrophysiologic study had three extrastimuli been 
used. The superior long-term follow-up in patients assigned to 
receive sotalol in the ESVEM trial is only consistent with the 
discordance findings between the two stimulation protocols. 
However, several studies (11,12) have shown that programmed 
stimulation protocols hould utilize at least up to three extra- 
stimuli to remain both sensitive and specific. Thus, many 
investigators (6) now advocate using up to three extrastimuli at 
each antiarrhythmic electrophysiologic study regardless of the 
number of extrastimuli necessary to induce ventricular tachy- 
cardia during the baseline study. 
The comparisons of the discordant rate of sotalol (6 of 20) 
with the discordant rate of other drugs (13 of 21) are based on 
small numbers of patients. The statistical significance is bor- 
derline, and further studies may be necessary to confirm these 
data. 
In the present study, intravenous procainamide and the 
drug combination of oral quinidine/mexiletine w re compared 
with oral sotalol. In the ESVEM trial, different drugs were 
compared with sotalol. However, the potential bias in the 
ESVEM long-term follow-up data appears dependent on the 
suppression rate of ventricular tachycardia induction at elec- 
trophysiologic study and not the specific drug tested. On the 
basis of recent studies (1-3), sotalol appears to have a higher 
suppression rate of ventricular tachycardia induction than 
conventional ntiarrhythmic agents. Therefore, as supported 
by our data, if -10% of all drug trials, regardless of the drug 
tested, are discordant when comparing a standard protocol 
with an ESVEM protocol, the drug or drug combination with 
a lower suppression rate of ventricular tachycardia induction 
will have a higher proportion of discordantly classified patients. 
Because ach of the drugs used in the ESVEM trial had a 
lower suppression rate of ventricular tachycardia nduction at 
electrophysiologic study than sotalol, it follows that sotalol's 
superior long-term follow-up may have resulted from a more 
accurate classification at initial electrophysiologic testing. 
Conclusions. In the present study, as was the case in the 
ESVEM trial, sotalol suppressed induction of ventricular 
tachycardia more often that the other drugs tested. The 
ESVEM programmed stimulation protocol predicted drug 
efficacy more often than the standard protocol (23% [41 of 
176] vs. 12.5% [22 of 176]). A constant overall discordant rate 
(10% to 12%) between the ESVEM and standard protocols 
occurred regardless of drug tested. However, the proportion of 
discordant trials with positive efficacy predictions was greater 
for drugs with lower overall efficacy prediction rates (procain- 
amide and quinidine/mexiletine, 62% [13 of 21]) than for 
sotalol (30% [6 of 20]). 
We must emphasize that although it is a logical extrapola- 
tion of our data, the superior long-term follow-up in patients 
assigned to receive sotalol in the ESVEM trial only indirectly 
supports our hypotheses. To verify that the patients with 
arrhythmia recurrences were the patients discordantly classi- 
fied by the ESVEM protocol, arandomized trial comparing the 
long-term results of drug therapy using the ESVEM and 
standard protocols would be necessary. 
References 
1. Mason JW. A comparison of seven antiarrhythmic drugs in patients with 
ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8. 
2. Nademanee K, Singh B. Effects of sotalol on ventricutar tachycardia and 
fibrillation produced by programmed lectrical stimulation: comparison with 
other antiarrhythmic agents. Am J Cardiol 1990;65:53A-7A. 
3. Kehoe R, MacNeil D, Zheutlin T, et al. Safety and efficacy of oral sotalol for 
sustained ventricular tachyarrhythmias refractory to other antiarrhythmiac 
agents. Am J Cardiol 1993;72:56A-66A. 
4. McPherson C, Rosenfeld L, Batsford W. Day-to-day reproducibility of 
responses to right ventricular programmed electrical stimulation: implica- 
tions for serial drug testing. Am J Cardiol 1985;55:689-95. 
5. Kudenchuk P, Kron J, Walance C, Cutler J, Griffith K, McAnulty J. 
Day-to-day reproducibility of mltiarrhythmic drug trials using programmed 
extrastimulus techniques for ventricular tachyarrhythmias as ociated with 
coronary artery disease. Am J Cardiol 1990;66:725-30. 
6. Josephson M. Clinical cardiac electrophysiology. Techniques and Interpre- 
tations, 2nd ed. Philadelphia: Lea & Febiger, 1993:643-5. 
7. Ferrick K, Luce J, Miller S, et al. Reproducibility of electrophysiologic 
testing during antiarrhythmic therapy for ventricular arrhythmias secondary 
to coronary artery disease. Am J Cardiol 1992;69:1296-9. 
8. The ESVEM Investigators. The ESVEM trial: electrophysiologic study 
versus electrocardiographic monitoring for selection of antiarrhythmic ther- 
apy of ventricular tachyarrhythmias. Circulation 1989;79:1354-60. 
9. Swerdlow C, Blum J, Winkle R, Griffin J, Ross D, Mason J. Decreased 
incidence of antiarrhythmic drug efficacy at electrophysiologic study associ- 
ated with the use of a third extrastimulus. Am Heart J 1982;104:1004-11. 
10. Rosenbaum M, Wilber D, Finkelstein D, Ruskin J, Garan H. Immediate 
reproducibility of electrically induced sustained monomorphic ventricular 
tachycardia before and during antiarrhythmic therapy. J Am Coll Cardiol 
1991;17:133-8. 
11. Morady F, DiCarlo L, Winston S, David JC, Scheinman MM. A prospective 
comparison oftriple extrastimuli and left ventricular stimulation i studies of 
ventricular tachycardia nduction. Circulation 1984;70:52-7. 
12. Kudenchuk PH, Kron J, Walance CG, et al. Reproducibility of arrhythmia 
induction with intracardiac electrophysiologic testing: patients with clinical 
sustained ventricular tachyarrhythmias. J Am Coll Cardiol 1986;7:819-28. 
